Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Lymphoma, B-Cell, Marginal Zone

Resectable HER2-positive Breast Cancer

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Carcinoma, Adenoid Cystic

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Lymphoma, T-Cell, Peripheral

Breast Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Inflammatory Breast Neoplasms

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Hodgkin Disease, Lymphoma

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HR+/HER2- Breast Cancer

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Triple Negative Breast Neoplasms

Breast Neoplasms

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

NeoSACT

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

MK-5890-003

TARMAC

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

EIC-SNACC

neoMono

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Linperlisib Combined With Chidamide in Patients With PTCL

APHINITY

PANSY

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

MK-3475-522

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

PELICAN

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

ARIADNE

FASCINATE-N

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

TCTN

KEYNOTE-756

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

FAST

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NeoHunter

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma